Strata Skin Sciences Q3 revenue $6.9M (-21% YoY); net loss narrows to $1.6M

STRATA Skin Sciences, Inc.

2025-Q3 EPS reported -$1.48 revenue$21,404,000

Revenue $6.9M (-21% YoY); net loss $1.6M (EPS -$0.36) vs $2.1M loss (EPS -$0.51) last year.
Global recurring revenue $5.5M (+3% YoY); equipment revenue $1.4M (-60%).
EBITDA slightly positive vs -$0.2M; cash $7.1M after $2.4M registered direct offering.
CMS recognized expanded CPT codes for XTRAC; COFEPRIS cleared TheraClearX in Mexico.
XTRAC install base 838 (-6); TheraClearX 161; avg gross billings per device $5,981 (+8.5%).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.